The Hippo

HOME| ADVERTISING | CONTACT US|

» » »

Valcyte for Cytomegalovirus in Children Nashua NH

The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

Fitzpatrick Sean W MD
(603) 882-2921
38 Tyler Street
Nashua, NH
 
Stephan LeBlanc
(603) 889-6671
155 Kinsley St
Nashua, NH
Specialty
Pediatrics

Data Provided by:
Gilbert David Levine, MD
(603) 577-4400
591 W Hollis St
Nashua, NH
Specialties
Pediatrics
Gender
Male
Education
Medical School: Univ Of Ia Coll Of Med, Iowa City Ia 52242
Graduation Year: 1979

Data Provided by:
Denise Eilen Youssef, MD
(603) 578-0245
8 Jenny Hill Ln
Nashua, NH
Specialties
Pediatrics
Gender
Female
Education
Medical School: Boston Univ Sch Of Med, Boston Ma 02118
Graduation Year: 1999

Data Provided by:
Gilbert David LeVine
(603) 577-4400
591 West Hollis Street
Nashua, NH
Specialty
Pediatrics

Data Provided by:
Das Anindita MD
(603) 886-5520
19 Tyler Street
Nashua, NH
 
Daigle Christopher MD
(603) 886-0290
10 Prospect Street
Nashua, NH
 
Cara L Mills, MD
(603) 891-4550
173 Daniel Webster Hwy
Nashua, NH
Specialties
Pediatrics
Gender
Female
Education
Medical School: George Washington Univ Sch Of Med & Hlth Sci, Washington Dc 20037
Graduation Year: 1994

Data Provided by:
Heart Center
(603) 889-4322
166 Kinsley Street Suite 301
Nashua, NH
 
Dr. Cara L Mills
(603) 891-4550
173 Daniel Webster Hwy
Nashua, NH
Specialty
Pediatrics

Data Provided by:

Valcyte for Cytomegalovirus in Children

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

CMV disease is a common infection among people who have had an organ transplant. Such patients may be infected with CMV before their surgeries, or be receiving organs that are infected, Roche said in a news release. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the company said, and in most cases lies dormant in the body. But when the immune system is weakened, CMV complications could affect the lungs, kidneys, nervous system, liver and gastrointestinal tract -- potentially leading to serious illness or death.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow for easier use in children, Roche said.

The drug has not been evaluated in transplant patients under 4 months of age, the company said.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu